225 citations,
July 2007 in “The Journal of Sexual Medicine” Knowing about finasteride's sexual side effects increases reported dysfunction.
28 citations,
September 2021 in “EMBO reports” Osthole inhibits the TRPV3 channel by binding to specific sites, potentially aiding drug development for skin diseases and cancers.
21 citations,
April 1998 in “Urology” Finasteride effectively treats BPH and hair loss but may cause sexual side effects.
19 citations,
September 1999 in “Talanta” New method measures minoxidil concentration faster, more accurately, and automatically.
9 citations,
September 1999 in “Journal of the European Academy of Dermatology and Venereology” Skin ulcers from interferon may not depend on the amount given.
3 citations,
April 2019 in “Human & Experimental Toxicology” Finasteride causes harmful organ changes in female mice.
1 citations,
February 2010 in “Proceedings of SPIE” Low level laser therapy may help regenerate hair cells in the ear after damage from gentamicin.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
The document is a detailed guide on skin conditions and treatments for dermatologists.
May 2017 in “Journal of The American Academy of Dermatology” Finasteride and dutasteride increase sexual dysfunction reports.
102 citations,
February 2008 in “The FASEB Journal” One minoxidil-sensitive potassium channel exists in human hair follicles.
27 citations,
August 1999 in “Urology” Finasteride improves urinary function in men for 2 years.
15 citations,
July 1991 in “International Journal of Dermatology” Laser Doppler velocimetry is a valuable noninvasive tool for skin blood flow research in dermatology.
6 citations,
April 2004 in “Dermatologic Surgery” Finasteride showed limited hair growth and low patient compliance in treating male pattern baldness.
6 citations,
September 1997 in “Prostate Cancer and Prostatic Diseases” Finasteride 5 mg effectively reduces urinary symptoms and PSA levels in men with enlarged prostates, with few sexual side effects.
4 citations,
July 2016 in “Dermatologic Surgery” Higher epinephrine concentration and specific injection sites increase scalp vasoconstriction time.
4 citations,
March 2015 in “Skin Research and Technology” Trichotillometry is a reliable method to measure hair strength and assess hair loss treatments.
3 citations,
May 1980 in “American Journal of Nursing” Scalp tourniquets did not significantly prevent hair loss from chemotherapy.
1 citations,
May 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” The symposium highlighted the importance of understanding disease mechanisms for targeted dermatology treatments.
Stopping minoxidil and draining fluid around the heart can save lives in rare cases.
January 2023 in “Brazilian Journals Editora eBooks” Girls with Autism Spectrum Disorder may show different symptoms than boys, leading to missed or delayed diagnoses.
Isotretinoin may cause temporary, reversible facial hair growth in some women.
Finasteride is popular for treating male hair loss but may increase the risk of serious prostate cancer and has other potential side effects.
May 2004 in “Dermatologic Surgery” Most men stopped using finasteride for baldness due to unsatisfactory results or were lost to follow-up, and those who continued saw minimal to moderate improvement.
July 1996 in “Annals of Internal Medicine” Taking high doses of fluconazole for a long time can cause reversible hair loss.
July 1996 in “Annals of Internal Medicine” Long-term high-dose fluconazole can cause reversible hair loss.
1707 citations,
December 2003 in “The New England Journal of Medicine” Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.
68 citations,
September 2003 in “British Journal of Dermatology” Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.
64 citations,
August 2019 in “Circulation” ADT, especially enzalutamide, may increase the risk of heart rhythm problems and sudden death in men.
52 citations,
February 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.